Randal Kirk

Latest Headlines

Latest Headlines

Biotech billionaire inks ocular pipeline pact with India's Sun

Biotech billionaire Randal "RJ" Kirk's synthetic biology company Intrexon has announced plans to partner with India's Sun Pharmaceutical on a pipeline of new drugs for ocular diseases, starting with dry age-related macular degeneration.

Biotech billionaire Kirk has a new, much bigger top line in mind

RJ Kirk has made billions in the biotech business by focusing on the development of new and improved drugs. But now the CEO of synthetic biotech pioneer Intrexon is thinking outside the healthcare box.

Upsized Intrexon IPO delivers another blockbuster success for billionaire Kirk

The sizzling market for biotech IPOs will end one day, but it won't be today. RJ Kirk's synthetic biology company Intrexon made its debut on Wall Street today and shares quickly zoomed up past the $22 mark, leaving the company with a hefty market value of more than $2 billion and its founder with another fortune.

Is biotech billionaire Kirk's Intrexon worth $1.4B?

Germantown, MD-based Intrexon, a synthetic biology outfit led by billionaire Randal Kirk, aims to sell 8.3 million shares at a proposed range of $14 to $16 per share.

Biotech billionaire Kirk reaches for $125M score in Intrexon IPO

Biotech billionaire Randal Kirk will try his luck on the hot IPO market. The CEO, chairman and president of Intrexon has filed papers with the SEC for an initial offering designed to raise up to $125 million, though the final amount often varies in the lead-up to a new listing.

Billionaire Kirk grabs $150M round for synthetic biology deals at Intrexon

A day after striking the latest in a series of its special "channel" collaborations, Intrexon has reloaded its bank account with a fresh $150 million infusion of cash, with significant added contributions from billionaire founder R.J. Kirk and his venture fund, Third Security.

Billionaire Kirk orchestrates $45M cell therapy tie-up in biotech deal spree

Biotech billionaire RJ Kirk has hitched another therapeutic developer to his synthetic biology wagon at Intrexon. This time it's Fibrocell Science, an Exton, PA-based developer with a personalized cell therapy for "aesthetic dermatology" on the market.

Billionaire's biotech seals second deal with Synthetic Biologics

Biotech startup Intrexon has expanded the synthetic biology shop's ties with drug developer Synthetic Biologics, picking up ownership in the partner as part of a deal focused on generating monoclonal antibodies for infectious diseases.

The Top 15 Biotech Venture Investments in H1 2012

These days, it's good to have your own money to bank on when you're growing a biotech company. It's also extraordinarily rare. The following 15 venture round qualified as the top investments of the first half, as tracked by Thomson Reuters and the National Venture Capital Association.

Forbes: How to get really, really rich in biotech

Forbes' Matthew Herper went searching for biotech billionaires on the magazine's annual list of the 400 richest Americans but could only scrape together three names: Patrick Soon-Shiong, who sold